The PROOV Study: Exploiting the Synergistic Effect of PARP Inhibition With Cisplatin and Hyperthermia During Interval Cytoreductive Surgery and HIPEC in Ovarian Cancer

NCT07460180 | Recruiting Phase 1

• 1 other identifier: M23PRV
• Study Type: interventional
• Target: 55
• Locations: 1 country
• Sites: 1

Brief Summary

The PROOV study is an open-label, monocenter, single-arm, prospective phase I/II trial with a safety lead-in, evaluating the feasibility of combining PARPi with HIPEC in stage III EOC patients. Phase I is a dose-finding phase with a time-to-event Bayesian Optimal Interval (TITE-BOIN) design, in which three doses of olaparib are evaluated to identify the optimal dose for the phase II part and future trials. The recommended phase II dose (RP2D) will be determined based on the experienced DLTs per dose level and the level of intra-tumor and systemic enzymatic PARP inhibition. During Phase II, the safety profile of the RP2D will be assessed in a total cohort of 40 patients. To provide a proof-of-concept, efficacy will be explored in both translational analyses and survival data.

Conditions

Ovarian Cancer; Epithelial Cancer; Fallopian Tube Cancer

Keywords

safety; efficacy; PARP inhibitor; HIPEC; Hyperthermic intraperitoneal Chemotherapy

Outcome Measures

Primary Outcomes (1)

• Safety and toxicity of combining PARP-inhibitors with HIPEC

  Safety lead in phase 1 part: evaluation of dose limiting toxicities by CTCAE v.5 and Clavien dindo from start PARP inhibition until 28 days postoperatively. Evaluated dosages are 100mg, 150mg and 300mg BID of olaparib. Further toxicity will be evaluated in phase 2, in which an additional number of patients will be treated with recommended phase 2 dose.

  4 years

Secondary Outcomes (1)

• The degree of PARP (enzymatic) inhibition

  4 years

Other Outcomes (8)

• Overall survival (OS)

  10 years

• Recurrence-free survival (RFS)

  10 years

• Tumor cell proliferation (Ki67)

  4 years

Study Arms (1)

PARPi (olaparib, Lynparza®)

EXPERIMENTAL

Drug: Olaparib

Interventions

Olaparib DRUG

seven days of PARPi (olaparib, Lynparza®) twice a day. The dosage will be either 100mg, 150mg or 300mg, depending on the phase of the trial.

PARPi (olaparib, Lynparza®)

Eligibility Criteria

• Age: 18 Years - 100 Years
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• In order to be eligible to participate in this study, a subject must meet all of the following criteria:
• Signed and written informed consent
• At least 18 years of age and able to understand patients' information
• FIGO stage III primary high-grade serous ovarian, fallopian tube, or extra-ovarian cancer.
• FIGO stage IV is allowed in the following situations:
• Resectable stage IV desease, such as local bowel involvement, iatrogenic abdominal wall metastases or umbilical lesions
• Stage IV based on cardiophrenic lymph nodes \<1cm
• The diagnosis should be confirmed with either histology or cytology. If the diagnosis of ovarian carcinoma is based on cytology only, immunohistochemistry, including keratin 7, keratin 20, p53, PAX8 should be considered for confirmation of the diagnosis (at the discretion of the pathologist)
• Eligible and planned for interval cytoreductive surgery with HIPEC
• Neo-adjuvant chemotherapy consists of at least 3 courses of carboplatin/paclitaxel
• Patients should have response or stable disease after NACT; no progression should occur
• Operability has been evaluated in a multidisciplinary team (MDT) meeting via CT scan, MRI or diagnostic laparoscopy and an optimal or complete interval CRS is deemed feasible
• Fit for major surgery, WHO performance status 0-2
• Adequate bone marrow function (hemoglobin level \>5.5 mmol/L, leukocytes \>3 x10\^9/L, platelets \> 100 x10\^9/L)
• Adequate hepatic function (ALT, AST, and bilirubin \< 2.5 times the upper limit of normal)

You may not qualify if:

• A potential subject who meets any of the following criteria will be excluded from participation in this study:
• History of previous malignancy treated with chemotherapy
• Opting for fertility-sparing surgery
• Concurrent use of potent inducers or inhibitors of CYP3A4 as assessed with the KNMP "G-standaard" that cannot be stopped temporarily

Sponsors & Collaborators

• The Netherlands Cancer Institute: lead

Study Sites (1)

NKI-AvL

Amsterdam, 1066CX, Netherlands

RECRUITING

MeSH Terms

Conditions

Ovarian Neoplasms; Fallopian Tube Neoplasms

Interventions

olaparib

Condition Hierarchy (Ancestors)

Endocrine Gland Neoplasms; Neoplasms by Site; Neoplasms; Ovarian Diseases; Adnexal Diseases; Genital Diseases, Female; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Genital Neoplasms, Female; Urogenital Neoplasms; Genital Diseases; Endocrine System Diseases; Gonadal Disorders; Fallopian Tube Diseases

Central Study Contacts

madelief schreuder-goedheijt

CONTACT

0205129111; m.schreudergoedheijt@nki.nl

leah frenkel

CONTACT

0205129111; l.frenkel@nki.nl

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 27, 2025
• First Posted: March 10, 2026
• Study Start: May 1, 2025
• Primary Completion (Estimated): May 1, 2027
• Study Completion (Estimated): May 1, 2032
• Last Updated: March 10, 2026

Record last verified: 2026-03

Locations

NL (1)